摘要
目的评价安络化纤丸联合恩替卡韦治疗慢性乙型肝炎肝纤维化的疗效。方法采用安络化纤丸联合恩替卡韦治疗慢性乙型肝炎30例,并与单用恩替卡韦治疗28例随机对照观察1年。结果联合治疗组治疗后患者各项肝纤维化指标下降幅度明显大于单用恩替卡韦治疗组(P<0.01)。结论联合用药更有利于阻断或逆转肝纤维化的形成和发展。
Objective To assess the therapeutic effect of anluohuaxian capsule combined with entecavir in treating chronic hepatitis B with Liver fibrosis. Methods Thirty patients with chronic hepatitis B in treatment group were treated with anluohuaxian capsule and entecavir, while twenty-eight patients in control group just received entecavir. The therapeutic duration in both groups was one years. Results In the treatment group,the decreased range of liver fibrosis index was much more significant than that of the control group（P〈 0.01 ）. Conclusion Combined medicine has more advantages for prevetning or reversing the formation and development of liver fibrosis.
出处
《中国现代医生》
2008年第11期88-89,共2页
China Modern Doctor
关键词
乙型肝炎
肝纤维化
恩替卡韦
安络化纤丸
治疗
Chronic hepatitis B
Liver fibrosis
Anluohuaxian capsule
Entecavir
Treatment
